The favorable effects of cilostazol on atherosclerosis were also demonstrable in diabetic patients with known peripheral artery disease (PAD); soluble CD40 ligand and hs-CRP levels were significantly decreased, and arterial compliance was modestly improved [14,15], However, the effects on arterial stiffness and various inflammatory markers related to the progression of atherosclerosis have not been evaluated in subjects with type 2 diabetes but not having coronary heart disease or PAD. The gene discussed is CD40LG; the disease is peripheral arterial disease.